Announcements Trials
Browse Landscape

Phase

Phase 3 4Phase 2 3Phase 1/2 3Phase 1 1

Status

Recruiting 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 1Sarcoma 1CNS 1

Conditions

Lung Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Bone Neoplasms 1

Interventions

pembrolizumab 38Specimen Handling 37Magnetic Resonance Spectroscopy 26Biopsy 26Cyclophosphamide 25Carboplatin 25fludarabine 21Nivolumab 20Gemcitabine 18Dexamethasone 18Paclitaxel 15Rituximab 13Bevacizumab 13Pemetrexed 12Docetaxel 12atezolizumab 11Cisplatin 11Lenalidomide 10Ipilimumab 10Fulvestrant 10venetoclax 9Prednisone 9Oxaliplatin 9olaparib 8fludarabine phosphate 8belantamab mafodotin 8Temozolomide 8Injections 8Fluorouracil 8abemaciclib 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × alectinib × 30 days × Clear all
NCT07560410 2026-05-11

Treatment of Truncated ALK-positive Bone Cancer Using Crizotinib (Xalkori) or Alectinib (Alecensa)

China Medical University Hospital

Phase 1/2 Not yet recruiting
10 enrolled
Sarcoma

Bone Neoplasms

NCT03202940 2026-05-08

A Phase IB/II Study of Alectinib Combined With Cobimetinib in Advanced ALK-Rearranged (ALK+) NSCLC

Massachusetts General Hospital

Phase 1/2 Active not recruiting
16 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04774718 2026-05-05

A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS Tumors

Hoffmann-La Roche

Phase 1/2 Recruiting
42 enrolled
CNS

Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡